Technology Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address… AIT News Desk Dec 14, 2022 - Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments - - NDI-034858 has potential best-in-class…
Technology Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858… AIT News Desk Dec 14, 2022 Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2)…
Technology Elevance Health to Acquire BioPlus AIT News Desk Nov 9, 2022 Acquisition deepens Elevance Health’s capabilities in specialty pharmacy Elevance Health announced that it has entered into an agreement with…
Life Sciences NantHealth Launches Eviti Connect for Autoimmune Diseases AIT News Desk May 5, 2021 Proven in oncology, the Eviti Connect payer solution expands to help reduce reimbursement inefficiencies and manage drug costs for disease that…
Regulation and Compliance Managment Immunovia Announces Positive Results From the IMMray PanCan-D Verification Study AIT News Desk Sep 29, 2020 Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, announced…